Targeting the RANK/RANKL pathway emerged as a rational strategy to arrest this process, and the anti-RANKL monoclonal antibody denosumab is currently approved in managing osteoporosis and preventing skeletal-related events secondary to bone metastases [2,3]. Here, TNFSF11 is linked to osteoporosis.